Related Experiment Video
Updated: Aug 15, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Comparison of strategies targeting Raf-1 mRNA in ovarian cancer
Peter Mullen1, Fiona McPhillips, Brett P Monia
1Cancer Research UK Centre, University of Edinburgh, Edinburgh, EH4 2XR, United Kingdom.
Abstract:
In this study, we characterize the uptake and specificity of a first-generation Raf-1 antisense oligonucleotide (ASO) (ISIS 5132) and compare it with a second-generation ASO (ISIS 13650) and an RNA interference approach. All three approaches resulted in inhibition of both Raf-1 expression and cellular growth. Specificity of the Raf-1 ASOs was confirmed by comparison with ASOs targeted against another Raf isoform (B-Raf) as well as mismatch sequences. Cellular uptake studies with FAM-labelled ISIS 5132 revealed that whilst the majority of cells treated at a low-intermediate plating density were labelled within 3 hr, cells treated at high density demonstrated neither Raf-1 protein knockout nor significant growth inhibition, following similar treatment. This lack of response at high cell densities was associated with reduced pERK and Raf-1 inhibition. Cell cycle analysis revealed that whilst SKOV-3 cells both accumulated in the S-phase of the cell cycle and showed enhanced annexin V levels, following Raf-1 ASO treatment; these effects were also demonstrated with first-generation but not second-generation mismatch oligonucleotides. Bromodeoxyuridine incorporation analysis suggested that these effects may indeed be partly attributable to sequence nonspecific effects. Finally, the combination of ISIS 5132 with either carboplatin or taxol showed enhanced growth inhibition, supporting the view that such ASOs may have a more effective clinical role when used in combination with cytotoxic agents.
Insights
This study compared Raf-1 antisense oligonucleotides (ASOs) and RNA interference, finding they inhibit Raf-1 expression and cell growth. However, high cell density reduced ASO effectiveness, suggesting combination therapy for enhanced clinical roles.
Area of Science:
- Molecular Biology
- Cancer Research
- Oligonucleotide Therapeutics
Background:
- Raf-1 is a key regulator of cell signaling pathways implicated in cancer.
- Antisense oligonucleotides (ASOs) and RNA interference (RNAi) are emerging therapeutic strategies for gene silencing.
- Understanding the uptake and specificity of these agents is crucial for their clinical development.
Purpose of the Study:
- To characterize the cellular uptake and specificity of a first-generation Raf-1 ASO (ISIS 5132).
- To compare the efficacy of ISIS 5132 with a second-generation ASO (ISIS 13650) and an RNAi approach.
- To evaluate the impact of cell density on ASO effectiveness and explore combination therapies.
Main Methods:
- Utilized FAM-labelled ISIS 5132 for cellular uptake studies at varying cell densities.
- Assessed Raf-1 expression and cellular growth inhibition following ASO and RNAi treatment.
- Performed specificity assays using B-Raf and mismatch ASOs.
- Conducted cell cycle and bromodeoxyuridine incorporation analyses.
- Investigated the combination of ISIS 5132 with carboplatin and taxol.
Main Results:
- All tested approaches (first-generation ASO, second-generation ASO, RNAi) inhibited Raf-1 expression and cellular growth.
- Cellular uptake and efficacy of ISIS 5132 were significantly reduced at high cell densities.
- Sequence-nonspecific effects were observed with first-generation mismatch oligonucleotides.
- Combination therapy with carboplatin or taxol enhanced growth inhibition.
Conclusions:
- Raf-1 ASOs and RNAi are effective in inhibiting Raf-1 expression and cell growth.
- Cell density is a critical factor influencing ASO efficacy.
- First-generation ASOs may exhibit sequence-nonspecific effects.
- Combination therapy holds promise for enhancing the clinical utility of Raf-1 ASOs.
More Related Videos
07:54Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
09:40Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
